stoxline Quote Chart Rank Option Currency Glossary
bluebird bio, Inc. (BLUE)
0.9664  -0.003 (-0.29%)    05-24 16:00
Open: 0.9692
High: 0.9989
Volume: 3,280,389
Pre. Close: 0.9692
Low: 0.946
Market Cap: 186(M)
Technical analysis
2024-05-27 4:44:28 PM
Short term     
Mid term     
Targets 6-month :  1.26 1-year :  1.43
Resists First :  1.08 Second :  1.23
Pivot price 1.02
Supports First :  0.85 Second :  0.7
MAs MA(5) :  0.98 MA(20) :  0.99
MA(100) :  1.18 MA(250) :  2.45
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  32.2 D(3) :  35.7
RSI RSI(14): 42.9
52-week High :  5.53 Low :  0.85
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BLUE ] has closed above bottom band by 16.7%. Bollinger Bands are 67.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 52 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1 - 1.01 1.01 - 1.01
Low: 0.93 - 0.94 0.94 - 0.94
Close: 0.95 - 0.97 0.97 - 0.98
Company Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Headline News

Sat, 25 May 2024
BLUE FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure ... - GlobeNewswire

Sat, 25 May 2024
Mitsubishi UFJ Asset Management Co. Ltd. Trims Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE) - Defense World

Fri, 24 May 2024
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird ... - Business Wire

Tue, 21 May 2024
Contact Levi & Korsinsky by May 28, 2024 Deadline to Join Class Action Against bluebird bio, Inc. (BLUE) - GlobeNewswire

Tue, 21 May 2024
IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the ... - AccessWire

Fri, 17 May 2024
BLUE INVESTOR ALERT: Kirby McInerney LLP Notifies bluebird bio, Inc. Investors of Upcoming Lead Plaintiff Deadline ... - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 193 (M)
Held by Insiders 1.0882e+008 (%)
Held by Institutions 0.3 (%)
Shares Short 29,750 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.3177e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -683.8 %
Return on Assets (ttm) -15.1 %
Return on Equity (ttm) -47.9 %
Qtrly Rev. Growth 17 %
Gross Profit (p.s.) 406.32
Sales Per Share 2.4977e+007
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -277 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0.4
Stock Dividends
Dividend 0
Forward Dividend 3.186e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android